<p>Fennec Pharmaceuticals（納斯達克股票代碼：FENC - 獲取免費報告）的股票在週二的一份報告中被 Wedbush 分析師重申為&#34;表現優異&#34;，據 RTT News 報道。他們目前對該股的目標價格為 14.00 美元，低於之前的 16.00 美元。Wedbush 的價格目標表明，該股有望上漲 139.32%，相對於上一個交易日的收盤價。</p>
<p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<p>FENC 已成為其他研究報告的主題。HC Wainwright 將 Fennec Pharmaceuticals 的目標股價從 18.00 美元降至 15.00 美元，並在 5 月 15 日星期三的一份報告中為該公司設定了&#34;買入&#34;評級。Craig Hallum 將 Fennec Pharmaceuticals 的目標股價從 20.00 美元降至 17.00 美元，並在 5 月 15 日星期三的一份研究報告中為該公司設定了&#34;買入&#34;評級。</p>
<p><strong>查看我們關於 FENC 的最新股票報告</strong></p>
<h2>Fennec Pharmaceuticals 股價下跌 6.4%</h2>
<p>FENC 股票在週二的午盤交易中下跌了 0.40 美元，報 5.85 美元。該股交易量為 192,799 股，相比其平均交易量 122,792 股有所增加。該股的 50 天簡單移動平均線為 6.37 美元，200 天簡單移動平均線為 8.35 美元。Fennec Pharmaceuticals 的 12 個月最低價為 5.30 美元，最高價為 11.92 美元。該公司的速動比率為 6.72，流動比率為 6.93，負債權益比為 9.86。該公司的市值為 1.5987 億美元，市盈率為 195.00，β係數為 0.29。</p>
<p>Fennec Pharmaceuticals（納斯達克股票代碼：FENC - 獲取免費報告）於 5 月 14 日星期二發佈了季度財報。該公司報告稱，該季度每股收益（EPS）為 0.41 美元，低於市場預期的 0.49 美元。該季度，公司營收為 2538 萬美元，超過分析師預期的 1046 萬美元。Fennec Pharmaceuticals 的淨資產回報率為-39.41%，淨利潤率為 6.33%。與去年同期相比，該公司當季每股收益為（0.23）美元。賣方分析師預計，Fennec Pharmaceuticals 今年財年的每股收益將為 0.36 美元。</p>
<h2>對 Fennec Pharmaceuticals 進行投資的對沖基金觀點</h2>
<p>一些大型投資者最近調整了他們對該股的持股。Tower Research Capital LLC TRC 在第四季度增加了對 Fennec Pharmaceuticals 的持股比例 107.3%。Tower Research Capital LLC TRC 現在擁有該公司的 3,048 股股票，價值 34,000 美元，較上一季度增加了 1,578 股。Acadian Asset Management LLC 在第二季度收購了 Fennec Pharmaceuticals 的新頭寸，價值約 49,000 美元。Jump Financial LLC 在第四季度收購了 Fennec Pharmaceuticals 的新頭寸，價值約 158,000 美元。Rhumbline Advisers 在第二季度將其對 Fennec Pharmaceuticals 的持股比例增加了 44.7%。Rhumbline Advisers 現在擁有該公司的 29,110 股股票，價值 178,000 美元，較上一季度增加了 8,987 股。最後，BNP Paribas Financial Markets 在第一季度將其對 Fennec Pharmaceuticals 的持股比例增加了 67.7%。BNP Paribas Financial Markets 現在擁有該公司的 32,769 股股票，價值 364,000 美元，較上一季度增加了 13,223 股。機構投資者擁有該公司 55.51% 的股份。</p>
<h2>Fennec Pharmaceuticals 公司簡介（獲取免費報告）</h2>
<p>Fennec Pharmaceuticals Inc 是一家生物製藥公司，致力於開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防兒童順鉑誘導性聽力損失或耳毒性的 III 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 Fennec Pharmaceuticals 更好</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>在市場抓住第二春之前購買 Holdings 股票</li>
<li>如何投資科技股，以及考慮的頂級科技股</li>
<li>3 只有潛力的股票可能成為多倍賺家</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>CEO 交換：星巴克因從 Chipotle 聘請新 CEO 而大漲 22%</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 在億萬富翁買光之前，先確保這支&#34;AI 燃料&#34;股票（來自市場背後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4"/></p>
<h2>現在是否值得投資 1000 美元購買 Fennec Pharmaceuticals？</h2>
<p>在考慮 Fennec Pharmaceuticals 之前，您會想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Fennec Pharmaceuticals 不在名單上。</p>
<p>儘管 Fennec Pharmaceuticals 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

FENC

<p>Wedbush 重申對 Fennec Pharmaceuticals 的 “跑贏市場” 評級，並設定目標價格為$14.00。該股票的潛在上漲空間為 139.32%，相較前一交易日收盤價。Fennec Pharmaceuticals 是一家生物製藥公司，致力於開發治療癌症的產品候選藥物</p>

<p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report)'s stock had its &#34;outperform&#34; rating reaffirmed by analysts at Wedbush in a note issued to investors on Tuesday, RTT News reports. They presently have a $14.00 target price on the stock, down from their prior target price of $16.00. Wedbush's price objective would suggest a potential upside of 139.32% from the stock's previous close.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（納斯達克股票代碼：FENC - 獲取免費報告）的股票在週二的一份報告中被 Wedbush 分析師重申為&#34;表現優異&#34;，據 RTT News 報道。他們目前對該股的目標價格為 14.00 美元，低於之前的 16.00 美元。Wedbush 的價格目標表明，該股有望上漲 139.32%，相對於上一個交易日的收盤價。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><p>FENC has been the subject of a number of other research reports. HC Wainwright reduced their price target on Fennec Pharmaceuticals from $18.00 to $15.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 15th. Craig Hallum reduced their target price on Fennec Pharmaceuticals from $20.00 to $17.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 15th.</p>
<div class="lb-trans"><p>FENC 已成為其他研究報告的主題。HC Wainwright 將 Fennec Pharmaceuticals 的目標股價從 18.00 美元降至 15.00 美元，並在 5 月 15 日星期三的一份報告中為該公司設定了&#34;買入&#34;評級。Craig Hallum 將 Fennec Pharmaceuticals 的目標股價從 20.00 美元降至 17.00 美元，並在 5 月 15 日星期三的一份研究報告中為該公司設定了&#34;買入&#34;評級。</p>
</div><p><strong>View Our Latest Stock Report on FENC</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 FENC 的最新股票報告</strong></p>
</div><h2>Fennec Pharmaceuticals Stock Down 6.4 %</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股價下跌 6.4%</h2>
</div><p>Shares of FENC traded down $0.40 during mid-day trading on Tuesday, reaching $5.85. 192,799 shares of the stock traded hands, compared to its average volume of 122,792. The stock has a fifty day simple moving average of $6.37 and a 200 day simple moving average of $8.35. Fennec Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $11.92. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86. The firm has a market cap of $159.87 million, a price-to-earnings ratio of 195.00 and a beta of 0.29.</p>
<div class="lb-trans"><p>FENC 股票在週二的午盤交易中下跌了 0.40 美元，報 5.85 美元。該股交易量為 192,799 股，相比其平均交易量 122,792 股有所增加。該股的 50 天簡單移動平均線為 6.37 美元，200 天簡單移動平均線為 8.35 美元。Fennec Pharmaceuticals 的 12 個月最低價為 5.30 美元，最高價為 11.92 美元。該公司的速動比率為 6.72，流動比率為 6.93，負債權益比為 9.86。該公司的市值為 1.5987 億美元，市盈率為 195.00，β係數為 0.29。</p>
</div><p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.08). The firm had revenue of $25.38 million for the quarter, compared to analysts' expectations of $10.46 million. Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. During the same period last year, the firm earned ($0.23) EPS. Sell-side analysts expect that Fennec Pharmaceuticals will post 0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（納斯達克股票代碼：FENC - 獲取免費報告）於 5 月 14 日星期二發佈了季度財報。該公司報告稱，該季度每股收益（EPS）為 0.41 美元，低於市場預期的 0.49 美元。該季度，公司營收為 2538 萬美元，超過分析師預期的 1046 萬美元。Fennec Pharmaceuticals 的淨資產回報率為-39.41%，淨利潤率為 6.33%。與去年同期相比，該公司當季每股收益為（0.23）美元。賣方分析師預計，Fennec Pharmaceuticals 今年財年的每股收益將為 0.36 美元。</p>
</div><h2>Hedge Funds Weigh In On Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Fennec Pharmaceuticals 進行投資的對沖基金觀點</h2>
</div><p>Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its stake in Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company's stock worth $34,000 after purchasing an additional 1,578 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Fennec Pharmaceuticals in the 2nd quarter valued at about $49,000. Jump Financial LLC acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at about $158,000. Rhumbline Advisers grew its position in shares of Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company's stock valued at $178,000 after buying an additional 8,987 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Fennec Pharmaceuticals by 67.7% during the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company's stock worth $364,000 after acquiring an additional 13,223 shares during the period. Institutional investors own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了他們對該股的持股。Tower Research Capital LLC TRC 在第四季度增加了對 Fennec Pharmaceuticals 的持股比例 107.3%。Tower Research Capital LLC TRC 現在擁有該公司的 3,048 股股票，價值 34,000 美元，較上一季度增加了 1,578 股。Acadian Asset Management LLC 在第二季度收購了 Fennec Pharmaceuticals 的新頭寸，價值約 49,000 美元。Jump Financial LLC 在第四季度收購了 Fennec Pharmaceuticals 的新頭寸，價值約 158,000 美元。Rhumbline Advisers 在第二季度將其對 Fennec Pharmaceuticals 的持股比例增加了 44.7%。Rhumbline Advisers 現在擁有該公司的 29,110 股股票，價值 178,000 美元，較上一季度增加了 8,987 股。最後，BNP Paribas Financial Markets 在第一季度將其對 Fennec Pharmaceuticals 的持股比例增加了 67.7%。BNP Paribas Financial Markets 現在擁有該公司的 32,769 股股票，價值 364,000 美元，較上一季度增加了 13,223 股。機構投資者擁有該公司 55.51% 的股份。</p>
</div><h2>Fennec Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 公司簡介（獲取免費報告）</h2>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家生物製藥公司，致力於開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防兒童順鉑誘導性聽力損失或耳毒性的 III 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Buy On Holdings Stock Before the Market Catches Its Second Wind?</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>3 High-Potential Stocks That Could Turn Into Multi-Baggers</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票，比 Fennec Pharmaceuticals 更好</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>在市場抓住第二春之前購買 Holdings 股票</li>
<li>如何投資科技股，以及考慮的頂級科技股</li>
<li>3 只有潛力的股票可能成為多倍賺家</li>
<li>什麼是債券市場假日？如何投資和交易</li>
<li>CEO 交換：星巴克因從 Chipotle 聘請新 CEO 而大漲 22%</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Secure this &#34;AI Fuel&#34; Stock Before the Billionaires Buy It All (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 在億萬富翁買光之前，先確保這支&#34;AI 燃料&#34;股票（來自市場背後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9148&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Fennec Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買 Fennec Pharmaceuticals？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Fennec Pharmaceuticals 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Fennec Pharmaceuticals 不在名單上。</p>
</div><p>While Fennec Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Fennec Pharmaceuticals 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Wedbush 重申對 Fennec Pharmaceuticals（NASDAQ:FENC）的跑贏大盤評級